The week in pharma: action, reaction and insight – week to October 7

9 October 2022

By Barbara Obstoj-Cardwell. Editor

M&A deals were a feature last week, with four announced on Monday. Important among these was US biotech Incyte revealing it is acquiring Villaris Therapeutics to expand its vitiligo portfolio with the latter’s auremolimab, in a deal that could cost it a much as $1.4 billion. Also, AstraZeneca’s Alexion rare diseases unit last Monday announced plans to buy LogicBio Therapeutics for a modest $68 million, but a whopping record-breaking 660% premium. On the deal-making front, Provention Bio entered into a co-promotion agreement with French pharma major Sanofi for its yet to be approved type 1 diabetes treatment teplizumab. Also of note, US pharma giant Pfizer presented new Phase III results on its prostate cancer drug Talzenna.

Incyte acquires Villaris to complement dermatology focus

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK